The complement component C5 is not responsible for the alternative pathway activity in rabbit erythrocyte hemolytic assays during eculizumab treatment

摘要

Dear Editors,Eculizumab is a therapeutic complement C5 inhibitor approved for the treatment of atypical hemolytic uremic syndrome(aHUS),paroxysmal nocturnal proteinuria(PNH),generalized myasthenia gravis and neuromyelitis optica spectrum disorder.Correct dosing of eculizumab is important to ensure complete complement blockade.Complement activity is often monitored by measuring either formation of the C5 activation product C5b-9 in vitro using an ELISA,independent of red blood cells,or by hemolytic assays measuring hemoglobin release from erythrocytes.Both approaches allow analysis of complement activation via the classical(CP)and alternative(AP)pathways.